These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

714 related articles for article (PubMed ID: 15085462)

  • 21. [-Anticoagulant drugs-].
    Gulba DC
    Herz; 1996 Feb; 21(1):12-27. PubMed ID: 8647576
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low-molecular-weight heparin in pediatric patients.
    Sutor AH; Chan AK; Massicotte P
    Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():31-9. PubMed ID: 15085464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis.
    Siragusa S; Cosmi B; Piovella F; Hirsh J; Ginsberg JS
    Am J Med; 1996 Mar; 100(3):269-77. PubMed ID: 8629671
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low molecular weight heparins in the outpatient management of venous thromboembolism.
    Bick RL
    Semin Thromb Hemost; 1999; 25 Suppl 3():97-9. PubMed ID: 10549723
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Subcutaneous unfractionated heparin for the treatment of venous thromboembolism.
    Kearon C
    Curr Opin Pulm Med; 2007 Sep; 13(5):398-402. PubMed ID: 17940484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term management of patients after venous thromboembolism.
    Kearon C
    Circulation; 2004 Aug; 110(9 Suppl 1):I10-8. PubMed ID: 15339876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment and prevention of venous thromboembolism.
    Hull RD; Pineo GF; Valentine KA
    Semin Thromb Hemost; 1998; 24 Suppl 1():21-31. PubMed ID: 9840689
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
    van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
    Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of ximelagatran in the treatment of venous thromboembolism.
    Schulman S
    Pathophysiol Haemost Thromb; 2005; 34 Suppl 1():18-24. PubMed ID: 15812200
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer-associated venous thrombosis in the surgical setting.
    Behranwala KA; Williamson RC
    Ann Surg; 2009 Mar; 249(3):366-75. PubMed ID: 19247020
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Major bleedings in the comparisons between low-molecular weight heparin versus oral anticoagulant therapy for venous thromboembolism.
    Ferretti G; Bria E; Giannarelli D; Carlini P; Felici A; Mandalà M; Ciccarese M; Papaldo P; Fabi A; Cognetti F
    Thromb Res; 2007; 119(4):525-9. PubMed ID: 16780933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of unfractionated heparin vs low molecular weight heparin in the treatment of acute deep vein thrombosis.
    Naz R; Naz S; Mehboob M; Khalid GH
    J Coll Physicians Surg Pak; 2005 Oct; 15(10):601-4. PubMed ID: 19810295
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis.
    Rodger M; Bredeson C; Wells PS; Beck J; Kearns B; Huebsch LB
    CMAJ; 1998 Oct; 159(8):931-8. PubMed ID: 9834718
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Therapeutic indications of low molecular weight heparins].
    Samama MM; Michaut-Paterno F
    Arch Mal Coeur Vaiss; 1991 Nov; 84(11 Suppl):1733-43. PubMed ID: 1662941
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cancer-associated thrombosis: focus on extended therapy with dalteparin.
    Bick RL
    J Support Oncol; 2006 Mar; 4(3):115-20. PubMed ID: 16553136
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of deep vein thrombosis using low-molecular-weight heparins.
    Groce JB
    Am J Manag Care; 2001 Nov; 7(17 Suppl):S510-5; discussion S515-23. PubMed ID: 11732662
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Duration of anticoagulant therapy after initial idiopathic venous thromboembolism.
    Frazee LA; Chomo DL
    Ann Pharmacother; 2003 Oct; 37(10):1489-96. PubMed ID: 14519045
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low-molecular-weight heparin in outpatient treatment of DVT.
    Yeager BF; Matheny SC
    Am Fam Physician; 1999 Feb; 59(4):945-52. PubMed ID: 10068716
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin.
    Anand S; Ginsberg JS; Kearon C; Gent M; Hirsh J
    Arch Intern Med; 1996 Aug 12-26; 156(15):1677-81. PubMed ID: 8694666
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low molecular weight heparin for the out-of-hospital treatment of venous thrombosis: rationale and clinical results.
    Hirsh J; Crowther M
    Thromb Haemost; 1997 Jul; 78(1):689-92. PubMed ID: 9198240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.